Traders purchased shares of Pfizer, Inc. (NYSE:PFE) on weakness during trading on Thursday. $129.75 million flowed into the stock on the tick-up and $56.25 million flowed out of the stock on the tick-down, for a money net flow of $73.50 million into the stock. Of all stocks tracked, Pfizer had the 10th highest net in-flow for the day. Pfizer traded down ($0.10) for the day and closed at $36.35

PFE has been the topic of several analyst reports. Credit Suisse Group downgraded Pfizer from an “outperform” rating to a “neutral” rating and dropped their price objective for the stock from $38.00 to $36.00 in a report on Thursday, July 20th. BMO Capital Markets restated a “buy” rating and set a $37.00 price objective on shares of Pfizer in a report on Wednesday, September 6th. Zacks Investment Research upgraded Pfizer from a “sell” rating to a “hold” rating in a research report on Friday, July 14th. Vetr lowered Pfizer from a “buy” rating to a “hold” rating and set a $35.71 target price for the company. in a research report on Wednesday, September 13th. Finally, Jefferies Group LLC reiterated a “neutral” rating and issued a $34.00 target price on shares of Pfizer in a research report on Friday, June 16th. Two investment analysts have rated the stock with a sell rating, nine have given a hold rating and twelve have issued a buy rating to the company. Pfizer presently has a consensus rating of “Hold” and a consensus price target of $38.10.

The stock has a 50-day moving average price of $35.19 and a 200 day moving average price of $33.77. The firm has a market capitalization of $216.13 billion, a P/E ratio of 26.58 and a beta of 1.00.

Pfizer (NYSE:PFE) last issued its earnings results on Tuesday, August 1st. The biopharmaceutical company reported $0.67 earnings per share (EPS) for the quarter, topping the Zacks’ consensus estimate of $0.65 by $0.02. Pfizer had a return on equity of 24.51% and a net margin of 15.84%. The business had revenue of $12.90 billion during the quarter, compared to analysts’ expectations of $13.08 billion. During the same period in the prior year, the firm posted $0.64 EPS. Pfizer’s quarterly revenue was down 1.9% compared to the same quarter last year. Equities research analysts expect that Pfizer, Inc. will post $2.56 earnings per share for the current fiscal year.

The business also recently announced a quarterly dividend, which will be paid on Friday, December 1st. Stockholders of record on Friday, November 10th will be issued a $0.32 dividend. The ex-dividend date is Thursday, November 9th. This represents a $1.28 dividend on an annualized basis and a dividend yield of 3.52%. Pfizer’s payout ratio is presently 94.12%.

In related news, insider Sally Susman sold 38,230 shares of the stock in a transaction that occurred on Tuesday, September 12th. The stock was sold at an average price of $35.00, for a total transaction of $1,338,050.00. Following the sale, the insider now directly owns 145,649 shares in the company, valued at approximately $5,097,715. The transaction was disclosed in a filing with the SEC, which can be accessed through this hyperlink. Also, CEO Ian C. Read sold 96,950 shares of the stock in a transaction that occurred on Friday, August 4th. The stock was sold at an average price of $34.00, for a total value of $3,296,300.00. The disclosure for this sale can be found here. Over the last 90 days, insiders have sold 464,521 shares of company stock worth $15,813,961. 0.06% of the stock is owned by corporate insiders.

Hedge funds and other institutional investors have recently added to or reduced their stakes in the stock. Asset Planning Services Ltd. grew its position in Pfizer by 4.9% during the 1st quarter. Asset Planning Services Ltd. now owns 2,961 shares of the biopharmaceutical company’s stock worth $101,000 after acquiring an additional 137 shares during the last quarter. Shine Investment Advisory Services Inc. bought a new stake in Pfizer during the 2nd quarter worth approximately $102,000. Mckinley Capital Management LLC Delaware bought a new stake in Pfizer during the 2nd quarter worth approximately $103,000. D. Scott Neal Inc. grew its position in Pfizer by 19.3% during the 2nd quarter. D. Scott Neal Inc. now owns 3,112 shares of the biopharmaceutical company’s stock worth $105,000 after acquiring an additional 504 shares during the last quarter. Finally, Herndon Capital Management LLC bought a new stake in Pfizer during the 2nd quarter worth approximately $120,000. Institutional investors and hedge funds own 68.99% of the company’s stock.

ILLEGAL ACTIVITY WARNING: This piece of content was first reported by The Cerbat Gem and is owned by of The Cerbat Gem. If you are reading this piece of content on another domain, it was illegally copied and reposted in violation of United States & international copyright legislation. The correct version of this piece of content can be read at https://www.thecerbatgem.com/2017/10/14/traders-buy-shares-of-pfizer-inc-pfe-on-weakness.html.

About Pfizer

Pfizer Inc (Pfizer) is a research-based global biopharmaceutical company. The Company is engaged in the discovery, development and manufacture of healthcare products. Its global portfolio includes medicines and vaccines, as well as consumer healthcare products. The Company manages its commercial operations through two business segments: Pfizer Innovative Health (IH) and Pfizer Essential Health (EH).

Receive News & Stock Ratings for Pfizer Inc. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Pfizer Inc. and related stocks with our FREE daily email newsletter.